J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Rinzimetostat efficacy wanes further as the company moves into phase 3.
Three private biotechs enter clinical trials, one targeting KRAS.
But PFS data are lacking, and there are questions about first and second-line plans.
The company will start three phase 3 trials of its G12D project this year.
But the company still has a lot to prove with ERAS-0015.
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
